Immunome Inc. 4

Horn Kinney, Chief Business Officer of Immunome Inc. (IMNM), exercised 90,616 stock options and sold 90,616 shares of common stock on August 4, 2026 under a Rule 10b5-1 plan.

On August 4, 2026, Immunome Inc. Chief Business Officer Horn Kinney exercised two employee stock option grants for a total of 90,616 shares of common stock (50,366 shares at an exercise price of $12.92 and 40,250 shares at $10.60) and immediately sold 90,616 shares of common stock at a weighted average price of $25.09 pursuant to a Rule 10b5-1 trading plan, resulting in an estimated gross sale value of approximately $2.27 million and option exercise costs of about $1.09 million. These transactions represent a classic exercise-and-sell programmatic liquidity event, with the derivative positions (the options) reduced to zero and the reported ownership shifting to zero shares of common stock in this account/line after the sale, though related footnotes indicate the options had standard four-year vesting schedules.

Filing Facts

CIK

1472012

Ticker

IMNM

Form

4

Source Type

fda

Accession

0001831215-26-000005

Alert Tier

7